Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Company Profile and bullboard matches:

CCHI , FACCF
Sort by: Date|Relevance

Interview Highlights from VRIC 2020

(Marin Katusa chats with Ross Beaty at VRIC 2020 | Image via Cambridge House) Stockhouse Media Alert: Podcast and video LIVE from the Vancouver Resource Investment Conference Cindy Broad of StockhouseMEDIA has been talking to everyone at the busy and upbeat VRIC 20...

Stockhouse Media Alert: Podcasts from XFUTURE 2019

The Extraordinary Future Conference attracted more than 2,500 attendees to the Vancouver Convention Centre to gain insight from high-profile speakers and analysts on all things emerging from the cannabis and tech sector. And Stockhouse Media covered the event LI...

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. Prior to the market open this morning Ra Pharmaceuticals Inc. (RARX:NASDAQ) and Brussels-based UCB (UCB:Euronext)...

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also anno...

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug

Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. Yesterday evening,...

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. After U.S. markets closed for trading ye...

The Best Way to Invest in the Coming Gold Boom

Since gold’s spectacular run last summer, it has surged even higher to nearly $1,600/oz. After waiting so patiently for gold to rise above its 2013 high, it might be tempting to take your minimal profit and run. Or, following the slight dip and stagn...
1 2 3